# Human Bioequivalence Study of Liposomal Amphotericin B for Injection

> **NCT06983665** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Huiyu Pharmaceutical Co., Ltd** · enrollment: 42 (estimated)

## Conditions studied

- Invasive Fungal Infections
- Neutropenic Fever
- Visceral Leishmaniasis

## Interventions

- **DRUG:** Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.)
- **DRUG:** Reference product (AmBisome®, Astellas Pharma US Inc.)

## Key facts

- **NCT ID:** NCT06983665
- **Lead sponsor:** Sichuan Huiyu Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-25
- **Primary completion:** 2025-11-10
- **Final completion:** 2026-04
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06983665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06983665, "Human Bioequivalence Study of Liposomal Amphotericin B for Injection". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06983665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*